Eye-Aging Reprogramming Trial Doses First Patient in Vision Rescue Study
TL;DR
Life Biosciences dosed the first patient in a small, safety-focused trial of ER-100, a gene therapy designed to reset epigenetic marks in retinal ganglion cells to reverse aging-like changes and potentially restore vision in open-angle glaucoma or NAION. Delivered by a virus and activated by a specific antibiotic, the study will enroll up to 18 participants and follow them for years, attracting both optimism about aging biology and warnings about safety risks and uncertain efficacy.
- World First: Patient Receives High-Risk Therapy to Make Cells Young Again ScienceAlert
- The first-ever reverse-aging drug was just injected into a human Business Insider
- This Biotech Startup Thinks It Can Reverse Vision Loss and Cellular Aging. It's Testing a Novel Therapy Now inc.com
- Re-Setting the Epigenetic Clock To Reverse Cellular Aging Technology Networks
- First human trial of reverse-aging drug begins Morning Brew
Want the full story? Read the original reporting
Read on ScienceAlert